Technology

Until now, only inaccurate diagnosis based on behaviour was possible (DSM-IV/V) for psychiatric diseases like ASD, ADHD and depression, often leading to misinterpretation and underdiagnosis. The introduction of accurate metabolic diagnostics as developed by APeT provides precise diagnosis of patients and the possibility to greatly enhance efficacy of treatment. Symptom treatment versus correction of the cause of a disorder For example, many drugs in depression aim at treatment of the symptoms like with re-uptake inhibition of serotonin. This leads inevitably to other problems in metabolic pathways further down the road. APeT looks at the origin of the serotonin problem, starting from the intake of the nutritional compounds that are essential for serotonin production and metabolism, to the final end products in the brain. At different places things can go wrong in the metabolic pathways leading to neurotransmission problems. APeT is capable of identifying many of these problems and correcting them with the administration of the required compounds with fine-tuned controlled dosing technology.

Background of APeT’s technology

Current focus is on Autism Spectrum Disorders (ASD) and ADHD, both affecting large populations that have detrimental effects on family lives and increasingly place a burden on society. Currently only behavioural (DSM-IV/V) and physical assessments are used to diagnose patients, leaving a wide gap for misinterpretation. Current standard of care treatment involves drugs that are potentially addictive, have many unwanted harmful side effects and which have very doubtful long-term effects. Hence there’s a great need for:

• Accurate biomarker based diagnostics
• Non-addictive drug treatment with no harmful, little to no side effects

The unique feature of APeT’s approach is combining proprietary metabolic diagnostics and know-how with subsequent therapy including patented drugs and nutraceuticals. APeT Holding BV’s metabolic diagnosis clearly distinguishes psychiatric patients with metabolic disorders. Most patients with a diagnosed tryptophan metabolism disorder have shown to greatly benefit from APeT’s first developed therapy. The therapy hardly gives rise to unwanted side effects, enabling patients to regain a normal family life, good health and jobs.

In cooperation with the University of Groningen a unique controlled release system has been developed which enhances efficacy and therapy loyalty. Following successful tests and treatments on many patients in non-clinical setting amongst others in cooperation with the Hans Berger Clinic for Epilepsy, Sleep Disorders and Neurological Learn and Developmental Disorders, APeT is currently rolling out clinical trials in order to register its drug treatment and validate its biomarkers in ASD and ADHD.

APeT is currently developing medication in combination with accurate metabolic diagnostics for indications like ADHD, autism, anxiety, depression, tics, schizophrenia, gastro-intestinal and sleep disorders. The introduction of accurate metabolic diagnostics as developed by APeT provides precise diagnosis of patients and the possibility to greatly enhance efficacy of treatment.